Survivin-positive circulating tumor cells as a marker for metastasis of hepatocellular carcinoma

Table 1 Clinical characteristics of 179 hepatocellular cancer patients

Clinical factor	n	1CTC count/5 mL	2mCTC count/5 mL	3Survivin (+)CTC count/5 mL	P value
		Median, SE	Median, SE	Median, SE
Sex
Male	119	17, 3.57	6, 1.11	9, 3.05	0.2511, 0.8192, 0.9093
Female	60	12, 9.61	6, 3.19	9.5, 7.88
Age
< 55 yeara	89	19, 4.28	9, 1.50	11, 3.54	0.7001, 0.1412, 0.4673
≥ 55 years	90	14, 5.75	4, 1.71	8, 4.88
HBV/HCV
Positive	130	17, 3.57	7, 1.16	10, 3.03	0.4021, 0.5392, 0.4363
Negative	49	13, 9.90	4, 3.12	6.5, 8.21
AFP levels
< 7.0	80	14, 5.85	5, 1.85	7, 4.66	0.2851, 0.812, 0.2543
≥ 7.0	99	22.5, 4.42	7.5, 1.45	11, 3.92
Cirrhosis
Yes	119	16, 3.43	6, 1.19	9.0, 2.78	0.4981, 0.6712, 0.8293
No	60	19.5, 10.03	7.5, 2.94	10, 8.67
TNM stage
I-II	79	14, 2.93	6, 1.04	6, 1.49	0.1111, 0.4332, 0.0023
III-IV	100	24, 6.29	8.50, 2.00	18, 5.95
BCLC stage
0-A	58	12.5, 3.04	4, 0.75	4, 1.25	0.0241, 0.0002, 0.0003
B-C	121	25, 4.94	9, 1.56	20, 4.64
Differentiation
Well	29	13, 2.04	5, 2.46	5, 1.70	0.0021 (well vs poor)
Moderate	92	14.5, 5.35	6, 1.77	8.5, 5.15	0.9702 (well vs poor)
Poor	58	37, 6.18	7.5, 1.55	24, 5.44	0.0053 (well vs poor)

¹Presents circulating tumor cell counts analysis.

²Presents mesenchymal circulating tumor cell counts analysis.

³Presents survivin positive circulating tumor cell counts analysis.

CTC: Circulating tumor cell; mCTC: Mesenchymal circulating tumor cell; AFP: α-fetoprotein.